SPC365

Left atrial appendage occlusion in combination with another cardiac procedure: a more efficient approach?

Session: SESSÃO DE POSTERS 58 – TROMBOEMBOLISMO
Speaker: Ana Lobato De Faria Abrantes

Congress: CPC 2025
Topic: ---
Theme: ---
Subtheme: ---
Session Type: Cartazes
FP Number: ---
Authors: Ana Lobato de Faria Abrantes; Miguel Nobre Menezes; Catarina Gregório; Miguel Azaredo Raposo; Diogo Ferreira; Pedro Carrilho Ferreira; Gustavo Lima Silva; João Silva Marques; Cláudia Jorge; João de Sousa; Pedro Cardoso; Fausto J. Pinto

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong>Introduction</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000">: Left atrial appendage occlusion (LAAO) is increasingly used to prevent stroke in patients (pts) with atrial fibrillation (AF), sometimes in combination with another cardiac procedure. Real-world data for combined procedures is, however, limited.</span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong>Purpose</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000">: To evaluate the safety and efficacy of combining LAAO with other cardiac procedures (cLAAO).</span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong>Methods</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000">: Single-center retrospective study included consecutive pts who underwent LAAO from 2009 to early December 2024, either as an isolated procedure (iLAAO) or in combination with another cardiac intervention. Groups were adjusted for CHA2DS2-VASc and HAS-BLED scores. Safety was defined as any acute complication and freedom from bleeding events during follow-up (FUP). Efficacy was assessed by freedom from thromboembolic events. Kaplan-Meier survival analysis was used for comparison outcomes.</span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong>Results</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000">:</span></span></span><br />
<span style="font-size:12pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000">Among 215 pts undergoing LAAO, 46 underwent cLAAO (57% male, age 75&plusmn;20 years, mean CHA2DS2-VASc 2.6&plusmn;1.2, HAS-BLED 3.16&plusmn;1). Indication for LAAO was similar in both groups -&nbsp; high bleeding risk/OAC intolerance in 80%, followed by ischemic events despite OAC in 10%. LAAO was combined with TAVI (37%), AF ablation (33%), and percutaneous mitral interventions (22%) and was the initial procedure in only 3 cases. Implanted devices were Watchman (56%), Watchman Flx (35%), and Amulet (9%). Acute complications were more frequent with cLAAO. There were 4 cases of cardiac tamponade (3 with Watchman first gen devices and 1 with the Amulet device), 3 of which in cLAAO. All tamponades were promptly managed percutaneously and occurred during the early years of LAAO (before May 2015) - Table 1. There was one case of major vascular complication in cLAAO and 3 cases of minor vascular complications in iLAAO. 51% of pts were discharged on dual antiplatelet therapy, 28% on NOACs, 14% on VKAs with aspirin, and 7% on aspirin alone, similar between groups. Over a mean FUP of 4 years, hemorrhagic and ischemic event rates were comparable (cLAAO:8(%) vs iLAAO:23(%) Long rank p=0.8, cLAAO:3(%) vs iLAAO: 2(%) Long rank p=0.9) in both groups.</span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong>Conclusion</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000">: Combining LAAO with another cardiac was associated with increased intra-procedural complication rates, but only earlier years of the procedure and with first generation devices. Long term, cLAAO had similar safety and efficacy when compared with iLAAO. cLAAO should be performed by experienced operators in high-volume centers, in order to ensure low complication rates.</span></span></span></p>

Our mission: To reduce the burden of cardiovascular disease
Visit our site

LISBOA
Campo Grande 28 - 13º |
1700-093 Lisboa
(+351) 21 797 06 85
(+351) 21 781 76 30
secretariado@spc.pt

COIMBRA
Rua de Olivença 11 - 7º Piso,
Sala 701, 3000-306 Coimbra
(+351) 239 83 81 01
(+351) 239 83 81 02
(+351) 239 83 81 03
cncdc@spc.pt

PORTO
Rua do Campo Alegre
803, Sala 8, 4150 Porto
(+351) 22 606 07 44
delegacao-norte@spc.pt